RAD51D and neoplasm: In addition, in the first surgery tumor sample, we found that although the RAD51D protein was basically not expressed, there were still some scattered expressed lesions, which might be PARPi-resistant and might be expanded under the selection pressure imposed by PARPi exposure, ultimately leading to drug resistance.